Severe winter asthma exacerbations can be prevented by omalizumab, but there is no carryover effect

Abstract

A pilot study of symptom profiles from a polyp vs an eosinophilic-based classification of chronic rhinosinusitis.

Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma

“…Sly et al (N = 27) [46] found no difference in the frequency of moderate exacerbations, but in the treatment period of 5 months 1 out of 14 in the omalizumab group (7%) and 6 out of 13 in the placebo group (46%) experienced a severe exacerbation [49]. The uncertainties of these results are large, because of the low number of included children and adolescents.…”

“…Children and adolescents: Four studies were identified reporting on exacerbations, but it was not possible to combine the results into a meta-analysis because of differences in the presentation of the outcome measure [43][44][45][46] and therefore the results are presented narratively.…”

“…Children and adolescents In the three studies reporting lung function [44][45][46], no significant difference was observed between the omalizumab and placebo group. In the study by Busse et al [44] the difference in FEV1%predicted was 0.92 (95% CI − 0.81; 2.64) in favour of the omalizumab group, and deemed not statistically significant.…”

“…Children and adolescents: Six papers [43][44][45][46][47][48] reported results from four RCTs [43][44][45][46] examining the effect of omalizumab in children and adolescents aged 6-18 years. Kulus et al [47] was a subgroup analysis among children and adolescents with severe asthma from the main study by Lanier et al [43], which also included moderate asthma cases, and Sorkness et al [48] was a post hoc analysis of age, asthma severity, dosing regimen, and prespecified biomarkers from the study by Busse et al [44].…”

“…The quality of evidence was considered low. Sly et al [46] presented no estimates of the effect on lung function, but concluded that no statistically significant or clinically relevant difference was observed.…”